Previous 10 |
Epizyme ( EPZM ) Q4 results : Revenues: $9.7M. More news on: Epizyme, Healthcare stocks news, Earnings news and commentary, Read more ...
Epizyme (NASDAQ: EPZM ): Q4 GAAP EPS of -$0.29 beats by $0.19 . More news on: Epizyme, Earnings news and commentary, Healthcare stocks news, Read more ...
Two Successive Tazemetostat NDA Submissions for Epithelioid Sarcoma and Follicular Lymphoma on Track for 2019 Productive FDA Meeting Supports Planned Accelerated Approval Submission for Relapsed/Refractory Follicular Lymphoma Patients with or without EZH2 Mutations Operating Runwa...
Epizyme, Inc . (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and full-year 2018 financial results and present at the 8 th ...
NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ON Semiconductor Corporation (NASDAQ:ON), Entegris, Inc. (NASDAQ:ENTG), U...
We covered Epizyme (EPZM) two years ago when the company was just breaking out with its lead drug candidate tazemetostat, an HMT inhibitor with great potential. The company has now completed some phase 2 trials, and so this is a good time to take another look at it. Let's first try to quickl...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...